0001628280-24-008979.txt : 20240305 0001628280-24-008979.hdr.sgml : 20240305 20240305165629 ACCESSION NUMBER: 0001628280-24-008979 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Konidaris Tasos CENTRAL INDEX KEY: 0001320982 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 24721810 MAIL ADDRESS: STREET 1: 103 JFK PARKWAY CITY: SHORT HILLS STATE: NJ ZIP: 07078 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 4 1 wk-form4_1709675759.xml FORM 4 X0508 4 2024-03-01 0 0001723128 Amneal Pharmaceuticals, Inc. AMRX 0001320982 Konidaris Tasos C/O AMNEAL PHARMACEUTICALS, INC. 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 0 1 0 0 Executive Vice President & CFO 0 Class A Common Stock 2024-03-01 4 M 0 36197 A 417037 D Class A Common Stock 2024-03-01 4 F 0 13257 5.47 D 403780 D Class A Common Stock 2024-03-03 4 M 0 45290 A 449070 D Class A Common Stock 2024-03-03 4 F 0 15897 5.47 D 433173 D Class A Common Stock 2024-03-03 4 M 0 57339 A 490512 D Class A Common Stock 2024-03-03 4 F 0 20126 5.47 D 470386 D Restricted Stock Units 2024-03-01 4 M 0 36197 0 D Class A Common Stock 36197 36197 D Restricted Stock Units 2024-03-03 4 M 0 45290 0 D Class A Common Stock 45290 90580 D Restricted Stock Units 2024-03-03 4 M 0 57339 0 D Class A Common Stock 57339 172019 D Restricted Stock Units 2024-03-04 4 A 0 175926 0 A Class A Common Stock 175926 175926 D Performance-Based Restricted Stock Units 2024-03-04 4 A 0 351852 0 A Class A Common Stock 351852 351852 D Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units vest in four equal annual installments beginning on March 4, 2025. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents a performance-based restricted stock unit grant of 175,926 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period. /s/ Denis Butkovic, Attorney-in-Fact 2024-03-05